Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Change in Accured Expenses (2019 - 2025)

Historic Change in Accured Expenses for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to $35.1 million.

  • Avidity Biosciences' Change in Accured Expenses rose 15449.02% to $35.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $82.4 million, marking a year-over-year increase of 25068.49%. This contributed to the annual value of $35.2 million for FY2024, which is 101869.63% up from last year.
  • Latest data reveals that Avidity Biosciences reported Change in Accured Expenses of $35.1 million as of Q3 2025, which was up 15449.02% from $47.2 million recorded in Q2 2025.
  • Avidity Biosciences' 5-year Change in Accured Expenses high stood at $47.2 million for Q2 2025, and its period low was -$15.3 million during Q1 2025.
  • Moreover, its 5-year median value for Change in Accured Expenses was $3.7 million (2023), whereas its average is $6.8 million.
  • As far as peak fluctuations go, Avidity Biosciences' Change in Accured Expenses tumbled by 20451.89% in 2023, and later surged by 231428.57% in 2024.
  • Over the past 5 years, Avidity Biosciences' Change in Accured Expenses (Quarter) stood at $2.2 million in 2021, then surged by 189.19% to $6.3 million in 2022, then tumbled by 40.62% to $3.7 million in 2023, then surged by 312.75% to $15.4 million in 2024, then skyrocketed by 128.06% to $35.1 million in 2025.
  • Its last three reported values are $35.1 million in Q3 2025, $47.2 million for Q2 2025, and -$15.3 million during Q1 2025.